Crohn’s Competition Coming
This article was originally published in The Pink Sheet Daily
Executive Summary
Humira filing will challenge J&J’s Remicade as Crohn’s disease treatment.
You may also be interested in...
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
Humira Clears FDA As First Self-Administered Biologic For Crohn’s Disease
Abbott’s adalimumab will compete with Johnson & Johnson’s Remicade in the Crohn’s market following approval of an sBLA for the indication.
Abbott Targets Simcor Filing For First Half 2007
Addition of Kos nearly doubles Abbott's 2007 dyslipidemia franchise.